Most individuals who are likely to benefit from APOL1-targeted therapeutic interventions have CKD associated with hypertension, diabetes mellitus, sickle cell disease, SLE, and other causes1,2—these are the same individuals enrolled in the CRIC, AASK, and Atherosclerosis Risk in Communities studies, thus making the study by Rosenberg et al. even more relevant and significant. This evidence concerns the gene APOL1 and sickle cell disease.